Despite CETP Loss, Lilly Says Long-Term Strategy Is Starting To Bear Fruit
Executive Summary
Drugs like baricitinib for rheumatoid arthritis, abemaciclib for breast cancer and solezumab for Alzheimer’s disease are among the six new molecular entities Lilly could file with regulators in the next 18 months.
You may also be interested in...
Lilly BioMedicines Head Ricks Tasked With Overseeing Growth Phase As Next CEO
Long-time CEO John Lechleiter, who led the company through a challenging period of enormous patent expirations, will step down at year's end.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.